Metabolic, autophagic, and mitophagic activities in cancer initiation and progression

Biomedical Journal

Volumn 39, Issue 2, 2016, Pages 98-106

  Hjelmeland, Anita ^a,b   Zhang, Jianhua ^b,c,d  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c University of Alabama at Birmingham   (United States)

^d BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

Autophagy; Cancer; Mitochondria; Mitophagy; Oxidative stress; Reactive species

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ADAPTOR PROTEIN; AUTOPHAGY PROTEIN 5; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PARKIN; PROTEIN BNIP3; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR NRF2;

AUTOPHAGY; BIOENERGY; CANCER GROWTH; CARCINOGENESIS; CELL DIFFERENTIATION; CELL INVASION; CELL METABOLISM; DNA DAMAGE; DNA MODIFICATION; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; MITOPHAGY; NITROSATIVE STRESS; NUCLEAR REPROGRAMMING; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; RESPIRATORY CHAIN; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION; CELL TRANSFORMATION; DRUG EFFECTS; METABOLISM; PHYSIOLOGY;

AUTOPHAGY; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; MITOCHONDRIA; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 84978286860     PISSN: 23194170     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bj.2015.10.002     Document Type: Review

References (168)

1. [1] Moncada, S., Palmer, R.M., Higgs, E.A., Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43 (1991), 109–142.
2. [2] Knowles, R.G., Moncada, S., Nitric oxide synthases in mammals. Biochem J 298 (1994), 249–258.
3. [3] Pacher, P., Beckman, J.S., Liaudet, L., Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87 (2007), 315–424.
4. [4] Hill, B.G., Dranka, B.P., Bailey, S.M., Lancaster, J.R. Jr., Darley-Usmar, V.M., What part of NO don't you understand? Some answers to the cardinal questions in nitric oxide biology. J Biol Chem 285 (2010), 19699–19704.
5. [5] Murphy, M.P., Holmgren, A., Larsson, N.G., Halliwell, B., Chang, C.J., Kalyanaraman, B., et al. Unraveling the biological roles of reactive oxygen species. Cell Metab 13 (2011), 361–366.
6. [6] Kalyanaraman, B., Teaching the basics of redox biology to medical and graduate students: oxidants, antioxidants and disease mechanisms. Redox Biol 8:1 (2013), 244–257.
7. [7] Lambeth, J.D., Neish, A.S., Nox enzymes and new thinking on reactive oxygen: a double-edged sword revisited. Annu Rev Pathol 9 (2014), 119–145.
8. [8] Thannickal, V.J., Fanburg, B.L., Reactive oxygen species in cell signaling. Am J Physiol Lung Cell Mol Physiol 279 (2000), L1005–L1028.
9. [9] Sauer, H., Wartenberg, M., Hescheler, J., Reactive oxygen species as intracellular messengers during cell growth and differentiation. Cell Physiol Biochem 11 (2001), 173–186.
10. [10] Landar, A., Darley-Usmar, V.M., Nitric oxide and cell signaling: modulation of redox tone and protein modification. Amino Acids 2 (2003), 313–321.
11. [11] Shiva, S., Moellering, D., Ramachandran, A., Levonen, A.L., Landar, A., Venkatraman, A., et al. Redox signalling: from nitric oxide to oxidized lipids. Biochem Soc Symp 71 (2004), 107–120.
12. [12] Circu, M.L., Aw, T.Y., Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med 48 (2010), 749–762.
13. [13] Higdon, A., Diers, A.R., Oh, J.Y., Landar, A., Darley-Usmar, V.M., Cell signalling by reactive lipid species: new concepts and molecular mechanisms. Biochem J 442 (2012), 453–464.
14. [14] Hensley, K., Robinson, K.A., Gabbita, S.P., Salsman, S., Floyd, R.A., Reactive oxygen species, cell signaling, and cell injury. Free Radic Biol Med 28 (2000), 1456–1462.
15. [15] Finkel, T., Holbrook, N.J., Oxidants, oxidative stress and the biology of ageing. Nature 408 (2000), 239–247.
16. [16] Christians, E.S., Benjamin, I.J., Proteostasis and REDOX state in the heart. Am J Physiol Heart Circ Physiol 302 (2012), H24–H37.
17. [17] Glasauer, A., Chandel, N.S., Targeting antioxidants for cancer therapy. Biochem Pharmacol 92 (2014), 90–101.
18. [18] Yang, Z., Klionsky, D.J., Eaten alive: a history of macroautophagy. Nat Cell Biol 12 (2010), 814–822.
19. [19] Chen, Y., Klionsky, D.J., The regulation of autophagy – unanswered questions. J Cell Sci 124 (2011), 161–170.
20. [20] Wang, K., Klionsky, D.J., Mitochondria removal by autophagy. Autophagy 7 (2011), 297–300.
21. [21] Feng, Y., He, D., Yao, Z., Klionsky, D.J., The machinery of macroautophagy. Cell Res 24 (2014), 24–41.
22. [22] Rubinsztein, D.C., Codogno, P., Levine, B., Autophagy modulation as a potential therapeutic target for diverse diseases. Nat Rev Drug Discov 11 (2012), 709–730.
23. [23] White, E., Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer 12 (2012), 401–410.
24. [24] Lee, J., Giordano, S., Zhang, J., Autophagy, mitochondria and oxidative stress: cross-talk and redox signalling. Biochem J 441 (2012), 523–540.
25. [25] Hill, B.G., Benavides, G.A., Lancaster, J.R. Jr., Ballinger, S., Dell'Italia, L., Jianhua, Z., et al. Integration of cellular bioenergetics with mitochondrial quality control and autophagy. Biol Chem 393 (2012), 1485–1512.
26. [26] Choi, A.M., Ryter, S.W., Levine, B., Autophagy in human health and disease. N Engl J Med 368 (2013), 1845–1846.
27. [27] Murrow, L., Debnath, J., Autophagy as a stress-response and quality-control mechanism: implications for cell injury and human disease. Annu Rev Pathol 8 (2013), 105–137.
28. [28] Giordano, S., Darley-Usmar, V., Zhang, J., Autophagy as an essential cellular antioxidant pathway in neurodegenerative disease. Redox Biol 2 (2013), 82–90.
29. [29] Zhang, J., Autophagy and mitophagy in cellular damage control. Redox Biol 1 (2013), 19–23.
30. [30] Dodson, M., Darley-Usmar, V., Zhang, J., Cellular metabolic and autophagic pathways: traffic control by redox signaling. Free Radic Biol Med 63 (2013), 207–221.
31. [31] Levonen, A.L., Hill, B.G., Kansanen, E., Zhang, J., Darley-Usmar, V.M., Redox regulation of antioxidants, autophagy, and the response to stress: implications for electrophile therapeutics. Free Radic Biol Med 71 (2014), 196–207.
32. [32] Redmann, M., Dodson, M., Boyer-Guittaut, M., Darley-Usmar, V., Zhang, J., Mitophagy mechanisms and role in human diseases. Int J Biochem Cell Biol 53 (2014), 127–133.
33. [33] Allison, D.B., Antoine, L.H., Ballinger, S.W., Bamman, M.M., Biga, P., Darley-Usmar, V.M., et al. Aging and energetics' 'Top 40' future research opportunities 2010–2013. F1000Res, 3, 2014, 219.
34. [34] Pryor, W.A., Stone, K., Oxidants in cigarette smoke. Radicals, hydrogen peroxide, peroxynitrate, and peroxynitrite. Ann N Y Acad Sci 686 (1993), 12–27.
35. [35] Eiserich, J.P., Vossen, V., O'Neill, C.A., Halliwell, B., Cross, C.E., van der Vliet, A., Molecular mechanisms of damage by excess nitrogen oxides: nitration of tyrosine by gas-phase cigarette smoke. FEBS Lett 353 (1994), 53–56.
36. [36] Loft, S., Poulsen, H.E., Cancer risk and oxidative DNA damage in man. J Mol Med Berl 74 (1996), 297–312.
37. [37] Sasco, A.J., Secretan, M.B., Straif, K., Tobacco smoking and cancer: a brief review of recent epidemiological evidence. Lung Cancer 45 (2004), S3–S9.
38. [38] Irani, K., Xia, Y., Zweier, J.L., Sollott, S.J., Der, C.J., Fearon, E.R., et al. Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science 275 (1997), 1649–1652.
39. [39] Irani, K., Goldschmidt-Clermont, P.J., Ras, superoxide and signal transduction. Biochem Pharmacol 55 (1998), 1339–1346.
40. [40] Vafa, O., Wade, M., Kern, S., Beeche, M., Pandita, T.K., Hampton, G.M., et al. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell 9 (2002), 1031–1044.
41. [41] Weinberg, F., Hamanaka, R., Wheaton, W.W., Weinberg, S., Joseph, J., Lopez, M., et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci USA 107 (2010), 8788–8793.
42. [42] Eyler, C.E., Wu, Q., Yan, K., MacSwords, J.M., Chandler-Militello, D., Misuraca, K.L., et al. Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. Cell 146 (2011), 53–66.
43. [43] Charles, N., Ozawa, T., Squatrito, M., Bleau, A.M., Brennan, C.W., Hambardzumyan, D., et al. Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell 6 (2010), 141–152.
44. [44] Heinecke, J.L., Ridnour, L.A., Cheng, R.Y., Switzer, C.H., Lizardo, M.M., Khanna, C., et al. Tumor microenvironment-based feed-forward regulation of NOS2 in breast cancer progression. Proc Natl Acad Sci USA 111 (2014), 6323–6328.
45. [45] Glynn, S.A., Boersma, B.J., Dorsey, T.H., Yi, M., Yfantis, H.G., Ridnour, L.A., et al. Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. J Clin Invest 120 (2010), 3843–3854.
46. [46] Puglisi, M.A., Cenciarelli, C., Tesori, V., Cappellari, M., Martini, M., Di Francesco, A.M., et al. High nitric oxide production, secondary to inducible nitric oxide synthase expression, is essential for regulation of the tumour-initiating properties of colon cancer stem cells. J Pathol 236 (2015), 479–490.
47. [47] Sablina, A.A., Budanov, A.V., Ilyinskaya, G.V., Agapova, L.S., Kravchenko, J.E., Chumakov, P.M., The antioxidant function of the p53 tumor suppressor. Nat Med 11 (2005), 1306–1313.
48. [48] Li, T., Kon, N., Jiang, L., Tan, M., Ludwig, T., Zhao, Y., et al. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 149 (2012), 1269–1283.
49. [49] Ramos-Gomez, M., Kwak, M.K., Dolan, P.M., Itoh, K., Yamamoto, M., Talalay, P., et al. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci USA 98 (2001), 3410–3415.
50. [50] Iida, K., Itoh, K., Kumagai, Y., Oyasu, R., Hattori, K., Kawai, K., et al. Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis. Cancer Res 64 (2004), 6424–6431.
51. [51] Xu, C., Huang, M.T., Shen, G., Yuan, X., Lin, W., Khor, T.O., et al. Inhibition of 7,12-dimethylbenz(a)anthracene-induced skin tumorigenesis in C57BL/6 mice by sulforaphane is mediated by nuclear factor E2-related factor 2. Cancer Res 66 (2006), 8293–8296.
52. [52] Yates, M.S., Kwak, M.K., Egner, P.A., Groopman, J.D., Bodreddigari, S., Sutter, T.R., et al. Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole. Cancer Res 66 (2006), 2488–2494.
53. [53] Cheung, K.L., Lee, J.H., Khor, T.O., Wu, T.Y., Li, G.X., Chan, J., et al. Nrf2 knockout enhances intestinal tumorigenesis in Apc(min/+) mice due to attenuation of anti-oxidative stress pathway while potentiates inflammation. Mol Carcinog 53 (2014), 77–84.
54. [54] Khor, T.O., Huang, M.T., Prawan, A., Liu, Y., Hao, X., Yu, S., et al. Increased susceptibility of Nrf2 knockout mice to colitis-associated colorectal cancer. Cancer Prev Res (Phila) 1 (2008), 187–191.
55. [55] Lau, A., Villeneuve, N.F., Sun, Z., Wong, P.K., Zhang, D.D., Dual roles of Nrf2 in cancer. Pharmacol Res 58 (2008), 262–270.
56. [56] Sporn, M.B., Liby, K.T., NRF2 and cancer: the good, the bad and the importance of context. Nat Rev Cancer 12 (2012), 564–571.
57. [57] DeNicola, G.M., Karreth, F.A., Humpton, T.J., Gopinathan, A., Wei, C., Frese, K., et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475 (2011), 106–109.
58. [58] Shibata, T., Ohta, T., Tong, K.I., Kokubu, A., Odogawa, R., Tsuta, K., et al. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci USA 105 (2008), 13568–13573.
59. [59] Zhang, P., Singh, A., Yegnasubramanian, S., Esopi, D., Kombairaju, P., Bodas, M., et al. Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Mol Cancer Ther 9 (2010), 336–346.
60. [60] Ooi, A., Wong, J.C., Petillo, D., Roossien, D., Perrier-Trudova, V., Whitten, D., et al. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell 20 (2011), 511–523.
61. [61] Adam, J., Hatipoglu, E., O'Flaherty, L., Ternette, N., Sahgal, N., Lockstone, H., et al. Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell 20 (2011), 524–537.
62. [62] Kansanen, E., Kuosmanen, S.M., Leinonen, H., Levonen, A.L., The Keap1-Nrf2 pathway: mechanisms of activation and dysregulation in cancer. Redox Biol 1 (2013), 45–49.
63. [63] Satoh, H., Moriguchi, T., Takai, J., Ebina, M., Yamamoto, M., Nrf2 prevents initiation but accelerates progression through the Kras signaling pathway during lung carcinogenesis. Cancer Res 73 (2013), 4158–4168.
64. [64] Hockenbery, D.M., Oltvai, Z.N., Yin, X.M., Milliman, C.L., Korsmeyer, S.J., Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 75 (1993), 241–251.
65. [65] Calle, E.E., Kaaks, R., Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4 (2004), 579–591.
66. [66] Calle, E.E., Rodriguez, C., Walker-Thurmond, K., Thun, M.J., Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348 (2003), 1625–1638.
67. [67] Warburg, O., Wind, F., Negelein, E., The metabolism of tumors in the body. J Gen Physiol 8 (1927), 519–530.
68. [68] Gambhir, S.S., Czernin, J., Schwimmer, J., Silverman, D.H., Coleman, R.E., Phelps, M.E., A tabulated summary of the FDG PET literature. J Nucl Med 42 (2001), 1S–93S.
69. [69] Gambhir, S.S., Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2 (2002), 683–693.
70. [70] Mankoff, D.A., Eary, J.F., Link, J.M., Muzi, M., Rajendran, J.G., Spence, A.M., et al. Tumor-specific positron emission tomography imaging in patients: [18F] fluorodeoxyglucose and beyond. Clin Cancer Res 13 (2007), 3460–3469.
71. [71] Flavahan, W.A., Wu, Q., Hitomi, M., Rahim, N., Kim, Y., Sloan, A.E., et al. Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. Nat Neurosci 16 (2013), 1373–1382.
72. [72] Mazurek, S., Boschek, C.B., Hugo, F., Eigenbrodt, E., Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol 15 (2005), 300–308.
73. [73] Christofk, H.R., Vander Heiden, M.G., Harris, M.H., Ramanathan, A., Gerszten, R.E., Wei, R., et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452 (2008), 230–233.
74. [74] Mazurek, S., Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int J Biochem Cell Biol 43 (2011), 969–980.
75. [75] Anastasiou, D., Yu, Y., Israelsen, W.J., Jiang, J.K., Boxer, M.B., Hong, B.S., et al. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat Chem Biol 8 (2012), 839–847.
76. [76] Iqbal, M.A., Gupta, V., Gopinath, P., Mazurek, S., Bamezai, R.N., Pyruvate kinase M2 and cancer: an updated assessment. FEBS Lett 588 (2014), 2685–2692.
77. [77] Langbein, S., Zerilli, M., Zur Hausen, A., Staiger, W., Rensch-Boschert, K., Lukan, N., et al. Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted. Br J Cancer 94 (2006), 578–585.
78. [78] Földi, M., Stickeler, E., Bau, L., Kretz, O., Watermann, D., Gitsch, G., et al. Transketolase protein TKTL1 overexpression: a potential biomarker and therapeutic target in breast cancer. Oncol Rep 17 (2007), 841–845.
79. [79] DeBerardinis, R.J., Mancuso, A., Daikhin, E., Nissim, I., Yudkoff, M., Wehrli, S., et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA 104 (2007), 19345–19350.
80. [80] Yang, C., Sudderth, J., Dang, T., Bachoo, R.M., McDonald, J.G., DeBerardinis, R.J., Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res 69 (2009), 7986–7993.
81. [81] Sonveaux, P., Copetti, T., De Saedeleer, C.J., Végran, F., Verrax, J., Kennedy, K.M., et al. Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis. PLoS One, 7, 2012, e33418.
82. [82] Kohn, A.D., Summers, S.A., Birnbaum, M.J., Roth, R.A., Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. J Biol Chem 271 (1996), 31372–31378.
83. [83] Calera, M.R., Martinez, C., Liu, H., Jack, A.K., Birnbaum, M.J., Pilch, P.F., Insulin increases the association of Akt-2 with Glut4-containing vesicles. J Biol Chem 273 (1998), 7201–7204.
84. [84] Plas, D.R., Talapatra, S., Edinger, A.L., Rathmell, J.C., Thompson, C.B., Akt and Bcl-xL promote growth factor-independent survival through distinct effects on mitochondrial physiology. J Biol Chem 276 (2001), 12041–12048.
85. [85] Edinger, A.L., Thompson, C.B., Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol Biol Cell 13 (2002), 2276–2288.
86. [86] Rathmell, J.C., Fox, C.J., Plas, D.R., Hammerman, P.S., Cinalli, R.M., Thompson, C.B., Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol Cell Biol 23 (2003), 7315–7328.
87. [87] Barata, J.T., Silva, A., Brandao, J.G., Nadler, L.M., Cardoso, A.A., Boussiotis, V.A., Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells. J Exp Med 200 (2004), 659–669.
88. [88] Elstrom, R.L., Bauer, D.E., Buzzai, M., Karnauskas, R., Harris, M.H., Plas, D.R., et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64 (2004), 3892–3899.
89. [89] Dang, C.V., Kim, J.W., Gao, P., Yustein, J., The interplay between MYC and HIF in cancer. Nat Rev Cancer 8 (2008), 51–56.
90. [90] Wise, D.R., DeBerardinis, R.J., Mancuso, A., Sayed, N., Zhang, X.Y., Pfeiffer, H.K., et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci USA 105 (2008), 18782–18787.
91. [91] DeBerardinis, R.J., Cheng, T., Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 29 (2010), 313–324.
92. [92] Anso, E., Mullen, A.R., Felsher, D.W., Matés, J.M., Deberardinis, R.J., Chandel, N.S., Metabolic changes in cancer cells upon suppression of MYC. Cancer Metab, 1, 2013, 7.
93. [93] Mathupala, S.P., Heese, C., Pedersen, P.L., Glucose catabolism in cancer cells. The type II hexokinase promoter contains functionally active response elements for the tumor suppressor p53. J Biol Chem 272 (1997), 22776–22780.
94. [94] Okamura, S., Ng, C.C., Koyama, K., Takei, Y., Arakawa, H., Monden, M., et al. Identification of seven genes regulated by wild-type p53 in a colon cancer cell line carrying a well-controlled wild-type p53 expression system. Oncol Res 11 (1999), 281–285.
95. [95] Schwartzenberg-Bar-Yoseph, F., Armoni, M., Karnieli, E., The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res 64 (2004), 2627–2633.
96. [96] Matoba, S., Kang, J.G., Patino, W.D., Wragg, A., Boehm, M., Gavrilova, O., et al. p53 regulates mitochondrial respiration. Science 312 (2006), 1650–1653.
97. [97] Bensaad, K., Tsuruta, A., Selak, M.A., Vidal, M.N., Nakano, K., Bartrons, R., et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126 (2006), 107–120.
98. [98] Hitosugi, T., Zhou, L., Elf, S., Fan, J., Kang, H.B., Seo, J.H., et al. Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. Cancer Cell 22 (2012), 585–600.
99. [99] Parsons, D.W., Jones, S., Zhang, X., Lin, J.C., Leary, R.J., Angenendt, P., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321 (2008), 1807–1812.
100. [100] Yan, H., Bigner, D.D., Velculescu, V., Parsons, D.W., Mutant metabolic enzymes are at the origin of gliomas. Cancer Res 69 (2009), 9157–9159.
101. [101] Yan, H., Parsons, D.W., Jin, G., McLendon, R., Rasheed, B.A., Yuan, W., et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 360 (2009), 765–773.
102. [102] Mardis, E.R., Ding, L., Dooling, D.J., Larson, D.E., McLellan, M.D., Chen, K., et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361 (2009), 1058–1066.
103. [103] Dang, L., White, D.W., Gross, S., Bennett, B.D., Bittinger, M.A., Driggers, E.M., et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462 (2009), 739–744.
104. [104] Zhao, S., Lin, Y., Xu, W., Jiang, W., Zha, Z., Wang, P., et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 324 (2009), 261–265.
105. [105] Pollard, P.J., Brière, J.J., Alam, N.A., Barwell, J., Barclay, E., Wortham, N.C., et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet 14 (2005), 2231–2239.
106. [106] Selak, M.A., Armour, S.M., MacKenzie, E.D., Boulahbel, H., Watson, D.G., Mansfield, K.D., et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 7 (2005), 77–85.
107. [107] Bardella, C., Pollard, P.J., Tomlinson, I., SDH mutations in cancer. Biochim Biophys Acta 1807 (2011), 1432–1443.
108. [108] Zhang, J., Teaching the basics of autophagy and mitophagy to redox biologists – mechanisms and experimental approaches. Redox Biol 4 (2015), 242–259.
109. [109] Lorin, S., Hamaï, A., Mehrpour, M., Codogno, P., Autophagy regulation and its role in cancer. Semin Cancer Biol 23 (2013), 361–379.
110. [110] Inoki, K., Corradetti, M.N., Guan, K.L., Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 37 (2005), 19–24.
111. [111] Liang, X.H., Jackson, S., Seaman, M., Brown, K., Kempkes, B., Hibshoosh, H., et al. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 402 (1999), 672–676.
112. [112] Qu, X., Yu, J., Bhagat, G., Furuya, N., Hibshoosh, H., Troxel, A., et al. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest 112 (2003), 1809–1820.
113. [113] Yue, Z., Jin, S., Yang, C., Levine, A.J., Heintz, N., Beclin 1, an autophagy gene essential for early embryonic development, is a haploin sufficient tumor suppressor. Proc Natl Acad Sci USA 100 (2003), 15077–15082.
114. [114] Mariño, G., Salvador-Montoliu, N., Fueyo, A., Knecht, E., Mizushima, N., López-Otín, C., Tissue-specific autophagy alterations and increased tumorigenesis in mice deficient in Atg4C/autophagin-3. J Biol Chem 282 (2007), 18573–18583.
115. [115] Takamura, A., Komatsu, M., Hara, T., Sakamoto, A., Kishi, C., Waguri, S., et al. Autophagy-deficient mice develop multiple liver tumors. Genes Dev 25 (2011), 795–800.
116. [116] Berthier, A., Seguin, S., Sasco, A.J., Bobin, J.Y., De Laroche, G., Datchary, J., et al. High expression of gabarapl1 is associated with a better outcome for patients with lymph node-positive breast cancer. Br J Cancer 102 (2010), 1024–1031.
117. [117] Liu, C., Xia, Y., Jiang, W., Liu, Y., Yu, L., Low expression of GABARAPL1 is associated with a poor outcome for patients with hepatocellular carcinoma. Oncol Rep 31 (2014), 2043–2048.
118. [118] Gao, C., Cao, W., Bao, L., Zuo, W., Xie, G., Cai, T., et al. Autophagy negatively regulates Wnt signalling by promoting Dishevelled degradation. Nat Cell Biol 12 (2010), 781–790.
119. [119] Zhang, Y., Wang, F., Han, L., Wu, Y., Li, S., Yang, X., et al. GABARAPL1 negatively regulates Wnt/ß-catenin signaling by mediating Dvl2 degradation through the autophagy pathway. Cell Physiol Biochem 27 (2011), 503–512.
120. [120] Boyer-Guittaut, M., Poillet, L., Liang, Q., Bôle-Richard, E., Ouyang, X., Benavides, G.A., et al. The role of GABARAPL1/GEC1 in autophagic flux and mitochondrial quality control in MDA-MB-436 breast cancer cells. Autophagy 10 (2014), 986–1003.
121. [121] Green, J.L., La, J., Yum, K.W., Desai, P., Rodewald, L.W., Zhang, X., et al. Paracrine Wnt signaling both promotes and inhibits human breast tumor growth. Proc Natl Acad Sci USA 110 (2013), 6991–6996.
122. [122] Cleary, A.S., Leonard, T.L., Gestl, S.A., Gunther, E.J., Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers. Nature 508 (2014), 113–117.
123. [123] Wei, H., Wei, S., Gan, B., Peng, X., Zou, W., Guan, J.L., Suppression of autophagy by FIP200 deletion inhibits mammary tumorigenesis. Genes Dev 25 (2011), 1510–1527.
124. [124] Guo, J.Y., Xia, B., White, E., Autophagy-mediated tumor promotion. Cell 155 (2013), 1216–1219.
125. [125] Janku, F., McConkey, D.J., Hong, D.S., Kurzrock, R., Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol 8 (2011), 528–539.
126. [126] Chen, N., Karantza, V., Autophagy as a therapeutic target in cancer. Cancer Biol Ther 11 (2011), 157–168.
127. [127] Denison, S.R., Wang, F., Becker, N.A., Schüle, B., Kock, N., Phillips, L.A., et al. Alterations in the common fragile site gene Parkin in ovarian and other cancers. Oncogene 22 (2003), 8370–8378.
128. [128] Cesari, R., Martin, E.S., Calin, G.A., Pentimalli, F., Bichi, R., McAdams, H., et al. Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. Proc Natl Acad Sci USA 100 (2003), 5956–5961.
129. [129] Picchio, M.C., Martin, E.S., Cesari, R., Calin, G.A., Yendamuri, S., Kuroki, T., et al. Alterations of the tumor suppressor gene Parkin in non-small cell lung cancer. Clin Cancer Res 10 (2004), 2720–2724.
130. [130] Wang, F., Denison, S., Lai, J.P., Philips, L.A., Montoya, D., Kock, N., et al. Parkin gene alterations in hepatocellular carcinoma. Genes Chromosom Cancer 40 (2004), 85–96.
131. [131] Fujiwara, M., Marusawa, H., Wang, H.Q., Iwai, A., Ikeuchi, K., Imai, Y., et al. Parkin as a tumor suppressor gene for hepatocellular carcinoma. Oncogene 27 (2008), 6002–6011.
132. [132] Veeriah, S., Taylor, B.S., Meng, S., Fang, F., Yilmaz, E., Vivanco, I., et al. Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet 42 (2010), 77–82.
133. [133] Yeo, C.W., Ng, F.S., Chai, C., Tan, J.M., Koh, G.R., Chong, Y.K., et al. Parkin pathway activation mitigates glioma cell proliferation and predicts patient survival. Cancer Res 72 (2012), 2543–2553.
134. [134] Sun, X., Liu, M., Hao, J., Li, D., Luo, Y., Wang, X., et al. Parkin deficiency contributes to pancreatic tumorigenesis by inducing spindle multipolarity and misorientation. Cell Cycle 12 (2013), 1133–1141.
135. [135] Jin, S.M., Youle, R.J., PINK1- and Parkin-mediated mitophagy at a glance. J Cell Sci 125 (2012), 795–799.
136. [136] Novak, I., Mitophagy: a complex mechanism of mitochondrial removal. Antioxid Redox Signal 17 (2012), 794–802.
137. [137] Ding, W.X., Yin, X.M., Mitophagy: mechanisms, pathophysiological roles, and analysis. Biol Chem 393 (2012), 547–564.
138. [138] Sarraf, S.A., Raman, M., Guarani-Pereira, V., Sowa, M.E., Huttlin, E.L., Gygi, S.P., et al. Landscape of the PARKIN-dependent ubiquitylome in response to mitochondrial depolarization. Nature 496 (2013), 372–376.
139. [139] Chen, Y., Dorn, G.W., 2nd. PINK1-phosphorylated mitofusin 2 is a Parkin receptor for culling damaged mitochondria. Science 340 (2013), 471–475.
140. [140] Wang, X., Winter, D., Ashrafi, G., Schlehe, J., Wong, Y.L., Selkoe, D., et al. PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility. Cell 147 (2011), 893–906.
141. [141] Lou, Y., Li, R., Liu, J., Zhang, Y., Zhang, X., Jin, B., et al. Mitofusin-2 over-expresses and leads to dysregulation of cell cycle and cell invasion in lung adenocarcinoma. Med Oncol, 32, 2015, 132.
142. [142] Jin, B., Fu, G., Pan, H., Cheng, X., Zhou, L., Lv, J., et al. Anti-tumour efficacy of mitofusin-2 in urinary bladder carcinoma. Med Oncol 28 (2011), S373–S380.
143. [143] Zhang, G.E., Jin, H.L., Lin, X.K., Chen, C., Liu, X.S., Zhang, Q., et al. Anti-tumor effects of Mfn2 in gastric cancer. Int J Mol Sci 14 (2013), 13005–13021.
144. [144] Rehman, J., Zhang, H.J., Toth, P.T., Zhang, Y., Marsboom, G., Hong, Z., et al. Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer. FASEB J 26 (2012), 2175–2186.
145. [145] Lee, Y., Lee, H.Y., Hanna, R.A., Gustafsson ÅB. Mitochondrial autophagy by Bnip3 involves Drp1-mediated mitochondrial fission and recruitment of Parkin in cardiac myocytes. Am J Physiol Heart Circ Physiol 301 (2011), H1924–H1931.
146. [146] Choe, S.C., Hamacher-Brady, A., Brady, N.R., Autophagy capacity and sub-mitochondrial heterogeneity shape Bnip3-induced mitophagy regulation of apoptosis. Cell Commun Signal, 13, 2015, 37.
147. [147] Chourasia, A.H., Tracy, K., Frankenberger, C., Boland, M.L., Sharifi, M.N., Drake, L.E., et al. Mitophagy defects arising from BNip3 loss promote mammary tumor progression to metastasis. EMBO Rep 16 (2015), 1145–1163.
148. [148] Bruick, R.K., Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc Natl Acad Sci USA 97 (2000), 9082–9087.
149. [149] Kramer, P.A., Darley-Usmar, V.M., The emerging theme of redox bioenergetics in health and disease. Biomed J 38 (2015), 294–300.
150. [150] Halliwell, B., Cell culture, oxidative stress, and antioxidants: avoiding pitfalls. Biomed J 37 (2014), 99–105.
151. [151] Xu, Y., Qian, S.Y., Anti-cancer activities of omega -6 polyunsaturated fatty acids. Biomed J 37 (2014), 112–119.
152. [152] Valko, M., Rhodes, C.J., Moncol, J., Izakovic, M., Mazur, M., Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 160 (2006), 1–40.
153. [153] Cairns, R.A., Harris, I.S., Mak, T.W., Regulation of cancer cell metabolism. Nat Rev Cancer 11 (2011), 85–95.
154. [154] Brandon, M., Baldi, P., Wallace, D.C., Mitochondrial mutations in cancer. Oncogene 25 (2006), 4647–4662.
155. [155] Murphy, M.P., How mitochondria produce reactive oxygen species. Biochem J 417 (2009), 1–13.
156. [156] Poillet-Perez, L., Despouy, G., Delage-Mourroux, R., Boyer-Guittaut, M., Interplay between ROS and autophagy in cancer cells, from tumor initiation to cancer therapy. Redox Biol 4 (2015), 184–192.
157. [157] Scherz-Shouval, R., Shvets, E., Fass, E., Shorer, H., Gil, L., Elazar, Z., Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4. EMBO J 26 (2007), 1749–1760.
158. [158] Alexander, A., Cai, S.L., Kim, J., Nanez, A., Sahin, M., MacLean, K.H., et al. ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS. Proc Natl Acad Sci USA 107 (2010), 4153–4158.
159. [159] Jain, A., Lamark, T., Sjøttem, E., Larsen, K.B., Awuh, J.A., Øvervatn, A., et al. p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response element-driven gene transcription. J Biol Chem 285 (2010), 22576–22591.
160. [160] Komatsu, M., Kurokawa, H., Waguri, S., Taguchi, K., Kobayashi, A., Ichimura, Y., et al. The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nat Cell Biol 12 (2010), 213–223.
161. [161] Perera, R.M., Stoykova, S., Nicolay, B.N., Ross, K.N., Fitamant, J., Boukhali, M., et al. Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism. Nature 524 (2015), 361–365.
162. [162] Kruiswijk, F., Labuschagne, C.F., Vousden, K.H., p53 in survival, death and metabolic health: a lifeguard with a licence to kill. Nat Rev Mol Cell Biol 16 (2015), 393–405.
163. [163] Ma, Z., Vosseller, K., Cancer metabolism and elevated O-GlcNAc in oncogenic signaling. J Biol Chem 289 (2014), 34457–34465.
164. [164] Marsh, S.A., Powell, P.C., Dell'italia, L.J., Chatham, J.C., Cardiac O-GlcNAcylation blunts autophagic signaling in the diabetic heart. Life Sci 92 (2013), 648–656.
165. [165] Guo, B., Liang, Q., Li, L., Hu, Z., Wu, F., Zhang, P., et al. O-GlcNAc-modification of SNAP-29 regulates autophagosome maturation. Nat Cell Biol 16 (2014), 1215–1226.
166. [166] Wani, W.Y., Boyer-Guittaut, M., Dodson, M., Chatham, J., Darley-Usmar, V., Zhang, J., Regulation of autophagy by protein post-translational modification. Lab Invest 95 (2015), 14–25.
167. [167] Harris, I.S., Treloar, A.E., Inoue, S., Sasaki, M., Gorrini, C., Lee, K.C., et al. Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. Cancer Cell 27 (2015), 211–222.
168. [168] Turcan, S., Rohle, D., Goenka, A., Walsh, L.A., Fang, F., Yilmaz, E., et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483 (2012), 479–483.